Celon Pharma SA (CLN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Celon Pharma SA (CLN) has a cash flow conversion efficiency ratio of -0.009x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-4.79 Million ≈ $-1.32 Million USD) by net assets (zł528.78 Million ≈ $145.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CLN equity financing ratio to measure how much of total assets are equity-financed.
Celon Pharma SA - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Celon Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Celon Pharma SA to evaluate the quality of earnings relative to operating cash generation.
Celon Pharma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celon Pharma SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Solar A/S
CO:SOLAR-B
|
0.215x |
|
QORIA Ltd
AU:QOR
|
-0.050x |
|
Indonesia Prima Property Tbk
JK:OMRE
|
-0.011x |
|
Cathay Chemical Works Inc
TW:1713
|
0.062x |
|
Real Asset Acquisition Corp.
NASDAQ:RAAQ
|
-0.001x |
|
QuickLogic Corporation
NASDAQ:QUIK
|
0.030x |
|
BAIRONG INC.CL.B -00002
F:6B5
|
N/A |
|
Sichuan Langsha Holding Ltd
SHG:600137
|
-0.016x |
Annual Cash Flow Conversion Efficiency for Celon Pharma SA (2012–2025)
The table below shows the annual cash flow conversion efficiency of Celon Pharma SA from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Celon Pharma SA (CLN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | zł363.25 Million ≈ $99.97 Million |
zł23.85 Million ≈ $6.56 Million |
0.066x | +357.83% |
| 2024-12-31 | zł445.21 Million ≈ $122.53 Million |
zł-11.34 Million ≈ $-3.12 Million |
-0.025x | -36.49% |
| 2023-12-31 | zł445.56 Million ≈ $122.62 Million |
zł-8.31 Million ≈ $-2.29 Million |
-0.019x | -90.39% |
| 2022-12-31 | zł479.65 Million ≈ $132.01 Million |
zł-4.70 Million ≈ $-1.29 Million |
-0.010x | -112.35% |
| 2021-12-31 | zł554.00 Million ≈ $152.47 Million |
zł43.95 Million ≈ $12.10 Million |
0.079x | -51.36% |
| 2020-12-31 | zł434.67 Million ≈ $119.63 Million |
zł70.90 Million ≈ $19.51 Million |
0.163x | +1537.33% |
| 2019-12-31 | zł445.04 Million ≈ $122.48 Million |
zł-5.05 Million ≈ $-1.39 Million |
-0.011x | -118.03% |
| 2018-12-31 | zł448.73 Million ≈ $123.50 Million |
zł28.24 Million ≈ $7.77 Million |
0.063x | +9.40% |
| 2017-12-31 | zł439.85 Million ≈ $121.05 Million |
zł25.30 Million ≈ $6.96 Million |
0.058x | +12.15% |
| 2016-12-31 | zł402.50 Million ≈ $110.77 Million |
zł20.65 Million ≈ $5.68 Million |
0.051x | -90.13% |
| 2015-12-31 | zł100.82 Million ≈ $27.75 Million |
zł52.37 Million ≈ $14.41 Million |
0.519x | +48.46% |
| 2014-12-31 | zł69.62 Million ≈ $19.16 Million |
zł24.36 Million ≈ $6.70 Million |
0.350x | +116.14% |
| 2013-12-31 | zł52.20 Million ≈ $14.37 Million |
zł8.45 Million ≈ $2.33 Million |
0.162x | -30.09% |
| 2012-12-31 | zł55.57 Million ≈ $15.29 Million |
zł12.87 Million ≈ $3.54 Million |
0.232x | -- |
About Celon Pharma SA
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.